Invivyd, Inc. (IVVD)
NASDAQ: IVVD · Real-Time Price · USD
1.900
+0.070 (3.83%)
At close: Mar 11, 2026, 4:00 PM EDT
1.840
-0.060 (-3.16%)
After-hours: Mar 11, 2026, 7:48 PM EDT
Invivyd Employees
As of December 31, 2024, Invivyd had 100 total employees, including 99 full-time and 1 part-time employees. The number of employees increased by 5 or 5.26% compared to the previous year.
Employees
100
Change (1Y)
5
Growth (1Y)
5.26%
Revenue / Employee
$534,260
Profits / Employee
-$524,890
Market Cap
536.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 100 | 5 | 5.26% | 99 | 1 |
| Dec 31, 2023 | 95 | 9 | 10.47% | 94 | 1 |
| Dec 31, 2022 | 86 | -17 | -16.50% | 84 | 2 |
| Dec 31, 2021 | 103 | - | - | 101 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Lyell Immunopharma | 300 |
| ADC Therapeutics | 265 |
| Prothena Corporation | 163 |
| Century Therapeutics | 150 |
| Ocugen | 95 |
| Neumora Therapeutics | 95 |
| Lexeo Therapeutics | 61 |
IVVD News
- 6 days ago - Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates - GlobeNewsWire
- 6 days ago - Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer - GlobeNewsWire
- 9 days ago - Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026 - GlobeNewsWire
- 9 days ago - Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 Antibodies - GlobeNewsWire
- 5 weeks ago - Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration - GlobeNewsWire
- 7 weeks ago - Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026 - GlobeNewsWire